Print Friendly, PDF & Email

NCT/Study#

NCT03666273 /

BAY1905254

An Open-Label, Phase 1, First-In-Human, Dose Escalation And Expansion Study To Evaluate The Safety, Tolerability, Maximum Tolerated Or Administered Dose, Pharmacokinetics, Pharmacodynamics And Tumor Response Profile Of The ILDR2 Function-Blocking Antibody BAY 1905254 In Patients With Advanced Solid Tumors (18789)

DISEASE GROUP:
Advanced Solid Tumors
current phase:
I
STUDY STATUS:
Active
Location:
Hackensack, NJ
For More information: